Immune to Cancer: The CRI Blog
-
European Regulators Approve Pembrolizumab (Keytruda) as First-line Treatment of Advanced Melanoma
The decision makes pembrolizumab the second PD-1-blocking drug to receive approval in Europe.
-
Phase 3 Trial Shows Nivolumab Improves Survival in Advanced Kidney Cancer
The trial ended early because data showed that patients lived longer on nivolumab compared to the standard-of-care…
-
A Cross-Country Biking Trip to Raise Awareness and Funding for Cancer Immunotherapy Research
In memory of his lifelong friend, Bryce, Nolan and his wife, Ileana, decided to bike across country…
-
Ready. Raise. Rise. For CRI
Raise a flag in honor of someone affected by cancer and help us win a $75,000 donation.
-
New Clinical Trials to Offer Immunotherapy as Frontline Treatment for Lung Cancer
Patients with lung cancer will soon be able to receive immunotherapy as first-line treatment on an experimental…
-
When Is a Spot Not a Spot?
A ten-year effort to optimize a ubiquitous laboratory assay finally pays off.
-
Giving 100% to ‘100 in 100’ – YOU DID IT!
A big thank you to all of our supporters who made $100K in 100 Days a success!
-
Immunotherapy: 5 Ways to Stop Cancer
The Cancer Research Institute has created a series of short, animated videos that explain the basics of…
-
White Out Cancer 2015
More than 1,000 posts from around the globe were shared in the third annual event.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.